Augie's Quest is a concentrated MDA research initiative speeding the search for ALS treatments and a cure.
In 2007, MDA and Augie’s Quest joined forces with the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass.
The multimillion-dollar partnership has created the largest ALS drug discovery project to date, which is conducting a thorough review of biochemical targets in ALS and drugs that may work on them.
Augie’s Quest funding enables ALS TDI to apply industrial-scale technology to ALS research in a way that has not been previously attempted.
In 2008, MDA established a nationwide consortium of five MDA-supported ALS centers that would each receive $100,000 per year to fund the infrastructure necessary for collaboration on clinical trials in ALS. The centers are located in Atlanta, Boston, Houston, New York and San Francisco.
In early 2013, MDA launched a neuromuscular disease registry through its national network of clinics. Through the registry, MDA aims to improve survival and quality of life for people with ALS and other neuromuscular diseases, and to expedite clinical trials and help make them more efficient. The Registry is being piloted at 25 MDA clinics to start; to learn more, check with your local MDA office.
In 2010, the U.S. Centers for Disease Control and Prevention opened the National ALS Registry to compile a large database of information about the incidence and prevalence of ALS, how the disease develops, and what types of treatments and interventions are beneficial.
People with ALS and/or their caregivers are encouraged to register at cdc.gov/als, where they will be asked to fill out short surveys about their and their families' health, their military background, and their environmental and occupational exposures.
In 2011, the ALS Research Collaboration, a University of Miami-based team dedicated to the study of familial (inherited) ALS, launched the fALS Connect online familial ALS registry. The developers of this registry aim to connect families affected by familial ALS with scientists who study the disease, in an effort to accelerate development of treatments and cures. Membership is open to those who have familial ALS and their blood relatives.